Evidence map›Paper›PMID 37686662›Full record

ArticleCancers2023

A Matched Molecular and Clinical Analysis of the Epithelioid Haemangioendothelioma Cohort in the Stafford Fox Rare Cancer Program and Contextual Literature Review.

Arwa Abdelmogod, Lia Papadopoulos, Stephen Riordan, Melvin Wong, Martin Weltman, Ratana Lim, Christopher McEvoy, Andrew Fellowes, Stephen Fox, Justin Bedő and 16 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 11 institutions in 1 country.

Arwa AbdelmogodLimestone Coast Local Health Network, Flinders University, Bedford Park, SA 5042, Australia.
Lia PapadopoulosThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Stephen RiordanPrince of Wales Clinical School, University of NSW, Randwick, NSW 2031, Australia.
Melvin WongRadiology Department, Prince of Wales Hospital, Randwick, NSW 2031, Australia.
Martin WeltmanDepartment of Gastroenterology, Nepean Hospital, Kingswood, NSW 2747, Australia.
Ratana LimThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Christopher McEvoyPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Andrew FellowesPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Stephen FoxPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Justin BedőThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Jocelyn PeningtonThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Kym PhamCentre for Cancer Research and Department of Clinical Pathology, University of Melbourne, Melbourne, VIC 3010, Australia.
Oliver HofmannCentre for Cancer Research and Department of Clinical Pathology, University of Melbourne, Melbourne, VIC 3010, Australia.
Joseph H A VissersCentre for Cancer Research and Department of Clinical Pathology, University of Melbourne, Melbourne, VIC 3010, Australia.ORCID 0000-0003-0435-6824
Sean GrimmondCentre for Cancer Research and Department of Clinical Pathology, University of Melbourne, Melbourne, VIC 3010, Australia.
Gayanie RatnayakeThe Royal Womens' Hospital, Parkville, VIC 3052, Australia.
Michael ChristieThe Royal Melbourne Hospital, Parkville, VIC 3052, Australia.
Catherine MitchellDepartment of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.ORCID 0000-0001-5596-9511
William K MurrayDepartment of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Kelly McClymontSullivan Nicolaides Pathology, Brisbane, QLD 4000, Australia.
Peter LukRoyal Prince Alfred Hospital, Camperdown, NSW 2050, Australia.
Anthony T PapenfussThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Damien KeeThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Clare L ScottThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
David GoldsteinThe Australian Rare Cancer Portal, BioGrid, Parkville, VIC 3051, Australia.
Holly E BarkerThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.ORCID 0000-0002-9350-5520
The University of Melbourne · AUPeter MacCallum Cancer Centre · AUWalter and Eliza Hall Institute of Medical Research · AUPrince of Wales Hospital · AURoyal Women's Hospital · AUCancer Australia · AUFlinders University · AUNepean Hospital · AURoyal Prince Alfred Hospital · AUSullivan Nicolaides Pathology · AUThe Royal Melbourne Hospital · AU

Funding

Cancer Council Victoria (Sir Edward Dunlop Fellowship in Cancer Research) n/aHerman Trust University of Melbourne n/aLorenzo and Pamela Galli Medical Research Trust n/aNational Health and Medical Research Council 1062702National Health and Medical Research Council 1081178National Health and Medical Research Council 1104348National Health and Medical Research Council 1116955Omico n/aStafford Fox Medical Research Foundation n/aVictorian Cancer Agency CRF16014
6 · The paper itself

Abstract

backgroundEpithelioid haemangioendothelioma (EHE) is an ultra-rare malignant vascular tumour with a prevalence of 1 per 1,000,000. It is typically molecularly characterised by a

methodsWe report a cohort of nine EHE cases with comprehensive histologic and molecular profiling from the Walter and Eliza Hall Institute of Medical Research Stafford Fox Rare Cancer Program (WEHI-SFRCP) collated via nation-wide referral to the Australian Rare Cancer (ARC) Portal. The diagnoses of EHE were confirmed by histopathological and immunohistochemical (IHC) examination. Molecular profiling was performed using the TruSight Oncology 500 assay, the TruSight RNA fusion panel, whole genome sequencing (WGS), or whole exome sequencing (WES).

resultsMolecular analysis of RNA, DNA or both was possible in seven of nine cases. The

conclusionsThis cohort of EHE cases provides molecular and histopathological characterisation and matching clinical information that emphasises the molecular patterns and variable clinical outcomes and adds to our knowledge of this ultra-rare cancer. Such information from multiple studies will advance our understanding, potentially improving treatment options.

Indexed as

ARC Portalbiomarkerepithelioid haemangioendotheliomafusion genesgenomicshistopathologyrare cancerSFRCPTAZYAP

Identifiers

PMID37686662
PMCPMC10487006
OpenAlexW4386417742

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.